Population Health & ICB Programmes
Population-Based Medicines Reviews
Reviews targeted by risk across a population.
What does a population-based medicines reviews service do?
Reviews targeted by risk across a population. BCS supports icbs, gp federations, primary care networks across the UK from hubs in Halifax and London, covering risk stratification, prioritised reviews, deprescribing.
Reviewed October 2026 by the BCS clinical services team.
What is this service?
Population-Based Medicines Reviews from Bespoke Clinical Services: reviews targeted by risk across a population. Every arrangement is built around your organisation — truly bespoke, never off-the-shelf.
What can BCS support?
- Risk stratification
- Prioritised reviews
- Deprescribing
- Impact reporting
How can it be delivered?
- Commissioned programmes
- Neighbourhood teams
- Outcomes reporting
- As a defined project — no permanent contract needed
Who makes clinical decisions?
Pharmacists and technicians complete tasks within their competence and agreed scope. Medical decisions, complex cases and prescription authorisation sit with the GP. All clinicians follow your organisation's clinical governance and procedures.
How clinical governance works →How does delivery start?
We agree the workload, scope, system access, escalation routes and reporting with you, complete clinician checks and induction, then start delivery. Progress is reviewed with you regularly.
Ways to commission →Why choose BCS?
BCS is a truly bespoke clinical services partner. We support 50+ PCNs and 300+ GP practices with 150+ clinical pharmacists, delivered from two hubs in Halifax and London. Every clinician is backed by our management layer, structured training, clinical supervision and quality assurance, and activity is reported clearly through the BCS Impact Dashboard.
How is it funded?
Typically commissioned by an ICB, federation or provider collaborative as a defined programme or service contract.
Read our funding and ARRS guide →Common questions
What does a population-based medicines reviews service do?
Reviews targeted by risk across a population. BCS supports icbs, gp federations, primary care networks across the UK from hubs in Halifax and London, covering risk stratification, prioritised reviews, deprescribing.
Who is Population-Based Medicines Reviews for?
It's designed for icbs, gp federations, primary care networks. Every arrangement is tailored to your organisation.
Can population-based medicines reviews be delivered remotely?
Yes. It can be delivered remotely, on-site, or a mix of both, from our hubs in Halifax and London.
Is population-based medicines reviews ARRS funded?
Typically commissioned by an ICB, federation or provider collaborative as a defined programme or service contract.
Who makes clinical decisions in population-based medicines reviews?
Pharmacists and technicians complete tasks within their competence and agreed scope. Medical decisions, complex cases and prescription authorisation sit with the GP. All clinicians follow your organisation's clinical governance and procedures.
How does population-based medicines reviews start?
We agree the workload, scope, system access, escalation routes and reporting with you, complete clinician checks and induction, then start delivery. Progress is reviewed with you regularly.
Do I need a full-time contract?
No. You can commission a defined project with an agreed scope and timeline, without a permanent staffing agreement.
Request Population-Based Medicines Reviews
Tell us a little about your organisation and we'll come back within one working day with a bespoke proposal.